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Abstract
Background: Primary hyperparathyroidism (PHPT) affects mainly cortical bone. It is thought that parathyroid
hormone (PTH) indirectly regulates the activity of osteoclasts by means of the osteoprotegerin/ligand of the
receptor activator of nuclear factor-b (OPG/RANKL) system. Several studies have confirmed that OPG
(osteoprotegerin) and RANKL (ligand of the receptor activator of nuclear factor-b) loci are determinants of bone
mineral density (BMD) in the general population. The aim of this study is to analyze the relationship between
fractures and BMD and the rs3102735 (163 A/G), rs3134070 (245 T/G) and rs2073618 (1181 G/C) SNPs of the OPG
and the rs2277438 SNP of the RANKL, in patients with sporadic PHPT.
Methods: We enrolled 298 Caucasian patients with PHPT and 328 healthy volunteers in a cross-sectional study. We
analyzed anthropometric data, history of fractures or renal lithiasis, biochemical determinants including markers for
bone remodelling, BMD measurements in the lumbar spine, total hip, femoral neck and distal radius, and
genotyping for the SNPs to be studied.
Results: Regarding the age of diagnosis, BMI, menopause status, frequency of fractures or renal lithiasis, we found
no differences between genotypes in any of the SNPs studied in the PHPT group. Significant lower BMD in the
distal radius with similar PTH levels was found in the minor allele homozygotes (GG) compared to heterozygotes
and major allele homozygotes in both OPG rs3102735 (163 A/G) and OPG rs3134070 (245 T/G) SNPs in those with
PHPT compared to control subjects. We found no differences between genotypes of the OPG rs2073618 (1181 G/C)
SNP with regard to BMD in the PHPT subjects. In the evaluation of rs2277438 SNP of the RANKL in PHPT patients,
we found a non significant trend towards lower BMD in the 1/3 distal radius and at total hip in the minor allele
homocygotes (GG) genotype group versus heterocygotes and major allele homocygotes (AA).
Conclusions: Our study provides the first evaluation of the relationship between SNPs of the OPG/RANK system
and sporadic PHPT. Subjects with PHPT and minor homocygote genotype (GG) for the OPG rs3102735 (163 A/G)
and OPG rs3134070 (245 T/G) SNPs have lower BMD in the distal radius, and this association does not appear to be
mediated by differences in PTH serum levels.
Background
Primary hyperparathyroidism (PHPT) is a common
endocrine disorder, usually sporadic and asymptomatic,
characterized by inappropriate hypersecretion of para-
thyroid hormone (PTH) and hypercalcemia. PHPT
expression in bone involves mainly cortical bone such as
the distal radius, with preservation of cancellous bone
[1-8] which suggests that the response to high levels of
PTH may differ depending on the skeletal structure [9],
having anabolic effects in cancellous bone and catabolic
actions at cortical sites. These findings in the pattern of
bone mineral density (BMD) in PHPT are the opposite
of those found in postmenopausal osteoporosis (OP).
However it has been demonstrated that a group of
* Correspondence: amadoja@unican.es
1Endocrinology Service, University Hospital “Marqués de Valdecilla” University
of Cantabria-IFIMAV. Avda. de Valdecilla, Santander 39008. SPAIN
Full list of author information is available at the end of the article
Piedra et al. BMC Medical Genetics 2011, 12:168
http://www.biomedcentral.com/1471-2350/12/168
© 2011 Piedra et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.patients with PHPT have lumbar OP that can improve
after parathyroidectomy [10].
It is thought that PTH indirectly stimulates osteoclasts
through neighbouring osteoblasts by inducing the ligand
of the receptor activator of nuclear factor-b (RANKL)
expression [7,11]. RANK is expressed on the osteoclasts
cell membrane and RANKL is a cytokine present on the
membranes of osteoblasts and when binding with
RANK, osteoclast differentiation, activation and survival
are stimulated. RANK-RANKL interactions, and its
effects, are prevented if RANKL binds with osteoprote-
gerin (OPG), a soluble receptor secreted by the osteo-
blasts. Genome wide association studies tested candidate
genes for their association with bone mineral density
( B M D )a n df o u n dt h a tt h eOPG gene is a determinant
of fractures and BMD in both the spine and the hip
[12,13] and that RANKL locus influences BMD in both
the spine and the hip also [13].
A number of studies analyzing the association between
different single nucleotide polymorphisms (SNPs) of the
OPG-RANK-RANKL system genes and bone density
have been carried out in the osteoporotic and general
populations, including a recent meta-analysis [14], but
none of these studied sporadic PHPT. SNPs rs3102735
(163 A/G) [15-17] and rs3134070 (245 T/G) [15,18] of
the OPG have been studied, showing lower BMD or
higher frequency of fractures related to the minor allele
(G) at different bone sites, mainly in postmenopausal
women. Regarding the rs2073618 (1181 G/C) SNP of
the OPG, the minor allele (C) has been related to higher
BMD [15,18-24]. Other studies could not demonstrate
these associations [25-28]. Among the SNPs of the
RANKL studied, the minor allele (G) of the rs2277438
has been related to a higher femoral neck compression
strength index [29] but not to BMD [19,29,30]. The aim
of this study is to analyze the relationship between
BMD and fractures and the three aforementioned SNPs
of the OPG and the rs2277438 SNP of the RANKL,i n
patients with sporadic primary hyperparathyroidism, a
model of chronic PTH hyperstimulation of the skeleton.
Methods
The study population consisted of 298 Caucasian
patients with sporadic PHPT. Cases were defined by
chronic hypercalcemia (total and/or ionic calcium) plus
high levels of PTH or plus inappropriately normal PTH
levels which means hypercalcemia and PTH values at
the upper limit of the normal range. We excluded the
few cases of PHPT that were part of a Multiple Endo-
crine Neoplasia Syndrome. After cautiously reviewing
the family clinical history we also excluded cases of pos-
sible hereditary isolated PHPT.
In order to study the allelic distribution in PHPT ver-
sus healthy population, 328 volunteers were enrolled
through face to face and written requests from hospital
workers, and through civic associations, religious groups
and geriatric residences. Written informed consent was
obtained from participants. This study was approved by
the Ethics Committee of our hospital (University Hospi-
tal “Marqués de Valdecilla”, Santander, Spain). Subjects
with history of diseases known to affect skeletal home-
ostasis, with non-Spanish ancestry, or who were taking
drugs which interfere with bone metabolism (bipho-
sphonates, strontium ranelate, corticosteroids, anti-epi-
leptics, estrogens, thiazides, hormonal replacement
therapy with estrogens in women beyond 55 years old)
were excluded. Fracture condition was defined by any
traumatic or spontaneous fracture at any location except
the nose, toe, head, jaw, skull and hands. The renal
lithiasis condition was defined by any detected lithiasis
by radiological exploration with or without symptoms.
Measurement of BMD
MD was quantified using X-ray absorptiometry (DXA,
Hologic, Walthan, MA, USA) in the lumbar spine (L2-4),
femoral neck, total hip and radius. The BMD measure-
ment variation coefficient was 1.2% in lumbar spine,
total hip locations and radius projection, and 1.4% in
the femoral neck.
DNA Analysis
Genomic DNA was extracted from venous blood (buffy
coat) by the Qiagen method (Hilden, Germany) and
stored at -40°C until analyzed. Polymerase chain reac-
tion (PCR) products were amplified in a 5 μl reaction
following the instructions of the manufacturer in an
Applied Thermal Cycler 9700 (Applied Biosystems).
Cycling conditions consisted of an initial denaturation
step at 95°C for 10 minutes and 48 cycles of denatura-
tion at 92°C for 30 seconds and annealing for 1 minute
at 60°C. After amplification, end-point fluorescence
reading and allele identification were carried out with
an ABI 7300 sequence detector (Applied Biosystems).
Random samples (8% of the total samples) were ana-
lysed twice for quality control.
The SNPs to be analyzed, 163 A/G (rs3102735)
located in promoter, 1181 G/C (rs2073618) located in
exon I and 245 T/G (rs3134070) located in promoter of
the OPG (chromosomal location 8q24, figure 1) [23]
and the rs2277438 from the RANKL (13q14) located in
a5 ’ untranslated region (UTR) [30] were chosen in rela-
tion to previous data in the literature suggesting possible
associations with bone mass and functional significance.
rs3102735 (163 A/G) is in strong linkage disequilibrium
with other loci (rs3134070 (245 T/G), 950 T/C, and
6890 A/C) [22]. The OPG SNPs rs2073618 (1181 G/C)
and rs3102735 (163 A/G) appear to be in different hap-
lotype blocks (Figure 1). rs2073618 (1181 G/C) SNP of
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to change from lysine to asparagine. rs2277438 from the
RANKL is a missense intronic substitution.
Analysis of the OPG rs3102735(163 A/G), rs3134070
(245 T/G) and rs2073618 (1181 G/C) polymorphisms.
Genotyping was performed with Custom Taqman
® SNP
Genotyping assays (Assay-by-Design) (Applied Biosystems,
Warrington, Cheshire, UK) using allele discrimination-
specific Taqman probes, labelled with VIC and FAM. Oli-
gonucleotide primers were designed, based on the
sequence of the OPG available in GenBank (AB008821).
The following primer sequences were used. For rs3102735
(163 A/G) SNP: CATGAATGGGACCACACTTTACAAG
(forward) and TGCTCTAGGGTTCGCTGTCT (reverse).
For rs3134070 (245 T/G) SNP: CCCTAGAGCAAA
GTGCCAAACT (forward) and AGCTTCCTACGCGCT-
GAAC (reverse). For rs2073618 (1181 G/C SNP):
CCAAGCCCCTGAGGTTTCC (forward) and CCCAGG-
GACTTACCACGAG (reverse).
Analysis of RANKL rs2277438 polymorphism. This SNP
was assayed by validated Taqman SNP Genotyping Assay.
TTGTTGGGGACATAAAGACTCTTGC[A/G]AGTAT-
GAATTTTTTGTTCTTAAGTC (context sequence).
Linkage structure was established from the Hapmap
Caucasian (CEU) population (http://www.Hapmap.org),
analyzed with Haploview 4.2 software [31].
Biochemical analysis
Fasting venous blood samples, for general biochemical
analysis and specific determinations, were obtained after
30 minutes of supine rest from an antecubital vein.
Samples were centrifuged immediately and serum was
stored at -40°C in multiple aliquots until assayed to
avoid freeze cycles. Total calcium (in serum and urine)
and alkaline phosphatase were measured by automated
methods in an ADVIA 2000 (Siemens Corp., Tarrytown,
NY, USA). Intra- and inter-assay variations were <2%.
Ionized calcium was measured by calcium-selective elec-
trodes automated in a Ciba Corning 634 Ca
++/pH Ana-
lyzer (Ciba Corning Diag. Corp, Medfield,
Massachusetts, USA). Intact PTH was determined by
automated immunoassay in a Liason (DiaSorin, Still-
water, Minnesota, USA). Sensitivity of assay was 5 pg/
mL. Intra- and inter-assay variations were <5 and <8%
respectively. 25-hydroxy-vitamin D was measured by
RIA after extraction (DiaSorin, Stillwater, Minnesota,
USA). The minimum detectable concentration was esti-
mated to be 1.5 ng/mL. Intra- and inter-assay precision
were 9.4 and 10.8%. Bone alkaline phosphatase (BAP)
was determined by immunoassay (Alkphase B kit, Metra
Biosystems, Mountain View, CA, USA). The minimum
detectable dose is 0.7 U/L. Intra- and inter-assay varia-
tions were 3.5 and 6.2% respectively. Specificity: bone:
100%; liver: 3-8%; intestine: 0.4%. Serum osteocalcin was
measured by immunoradiometric assay (IRMA)
(OSTEO-RIACT kit, CIS Bio international, Gif-sur-
Yvette, France). The sensitivity of the osteocalcin was
0.4 ng/mL. Intra- and inter-assay variations are 2.0 and
4.4% respectively. Collagen type I N-terminal propeptide
levels were measured by RIA (Orion Diagnostica, Espoo,
Finland). Sensitivity of the propeptide is 2 μg/L. Intra-
and inter-assay variations are 8.75 and 5% respectively.
Crosslaps were measured by ELISA (Nordic Bioscience
Diagnostics, Herlev Hovedgade, Denmark). Sensitivity of
assay is 0.010 ng/mL; intra- and inter-assay variations
were 5.1 and 6.6% respectively. All biochemical and
DXA procedures were performed at time of diagnosis
and before any specific treatment had been initiated.
Statistical analysis
The results were processed with the computer package
SPSS (Statistical Package for Social Sciences, Chicago,
IL, USA). Normal or non-normal distribution of the
variables under study was tested with the Kolmogorov-
Smirnov test. All data were expressed as mean ± SD
(standard deviation of the mean), or the median and
range for non-normal variables. Comparisons between
PHPT patients and 114 age and gender matched con-
trols from the 328 total control group were tested by
Student t-test and Mann-Whitney U for normally and
non-normally distributed parameters. Allele frequencies
Exon 4 Exon 1 Exon 2 Exon 3 Exon 5
149 T/C
163 A/G
209 G/A
245 T/G
950 T/C
1181 G/C
1217 C/T 6890 A/C 6833 A/G
Exon 4 Exon 1 Exon 2 Exon 3 Exon 5
149 T/C
163 A/G
209 G/A
245 T/G
950 T/C
1181 G/C
1217 C/T 6890 A/C 6833 A/G
Figure 1 Polymorphisms in the proximal region of the OPG
gene. The 245 T/G (rs3134070) and 163 A/G (rs 3102735) SNPs
appear to be in the same haplotype block (Promoter) but in different
block (Exon 1) from the 1181 G/C (rs 2073618) SNP. The linkage
between SNP pairs is shown in the figures as D’. The numbers in the
figures represent the Levontin distance (100 × D’); numbers are
omitted from SNP pairs showing a D’ of 100. The correlation (r
2)
between the OPG loci studied was: rs3102735-rs2073618 = 0.01;
rs3102735-rs3134070 = 0.39; rs3134070-rs2073618 = 0.09.
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2 test was used to
identify significant departure from the Hardy-Weinberg
equilibrium and for allele frequencies related to control
and PHPT patients as well. In order to test association
between the SNPs and PHPT, an odds ratio between
cases and controls was calculated in addition. Fracture
and nephrolithiasis frequency in the different genotype
groups was tested by c
2. All shown data were adjusted
for age, body mass index (BMI) and sex. Differences in
age, BMI, BMD and bone remodelling markers between
genotype groups were examined using the One-way
ANOVA or Kruskal-Wallis test. If global test results
were significant, between-group differences were then
tested after Bonferroni correction for multiple compari-
sons (with a cut-off p value of 0.0167) except for BMD
1/3 radius and osteocalcin. In these two cases we used
the Mann-Whitney U test (with a confidence interval of
98.3%) between pairs of alleles because there was only
one subject in GG group who had osteocalcin and BMD
1/3 radius studied.
Results
General characteristics, bone biochemical parameters
(non normal distribution) and BMD measurements
(normal distribution) of both patients and control sub-
jects are shown in Table 1. The presence of PHPT was
excluded in all of the control subjects by measuring cal-
cium and PTH. There were no differences regarding
age, sex and menopause status between groups. The 25-
OH-Vit D status was similar in both groups. BMI was
s i g n i f i c a n t l yh i g h e ri nP H P Tt h a ni nc o n t r o lg r o u p .A s
expected, we found significant high levels of bone bio-
chemical parameters in the PHPT group compared with
the control group and lower BMD in the PHPT patients
than in the control subjects at the three studied sites.
Allelic frequencies did not deviate from Hardy-Wein-
berg equilibrium. Genotype frequencies for controls and
primary hyperparathyroidism subjects showed no differ-
ences in any of the SNPs studied (Tables 2 and 3).
Regarding the age of diagnosis, BMI, menopause sta-
tus, frequency of fractures or renal lithiasis, we found
no differences between genotypes in any of the SNPs
studied in the PHPT group (Additional File 1) nor in
control subjects.
Relationship between the different SNPs studied and
BMD and bone remodelling markers
SNP 163 A/G OPG (rs 3102735)
In PHPT patients, BMD at the 1/3 distal radius was sig-
nificantly lower in the minor allele homozygote group
(GG) versus the other two groups (p = 0.039); (GG-AA
p = 0.038; GG-AG p = 0.037) (Table 4). There were no
differences between the major allele homozygote and
heterozygote group. Analysis of BMD in the lumbar
spine or hip did not show any difference between geno-
types. PTH, total and ionized calcium, P1NP, b Cross-
laps, osteocalcin and bone alkaline phosphatase (BAP)
showed a trend (not statistically significant) to higher
levels in the minor allele homozygote group versus the
other two groups. There were no differences in vitamin
D levels among the three groups (data not shown except
for PTH (Table 4, Additional File 2). These results were
not different in the subgroup of women and we found
no difference in their menopausal status between the
three genotype groups.
In the control group, we did not find any difference
between genotypes regarding BMD at three sites (Addi-
tional File 3).
SNP 245 T/G OPG (rs3134070)
In PHPT patients, BMD in the 1/3 distal radius was sig-
nificantly lower in the minor allele (GG) homozygote
group versus the other two groups despite its low
Table 1 General features of control and PHPT subjects
Control group PHPT group p
(n = 114
+) (n = 298)
Age (years) 59 ± 13 62 ±13 0.052
♀/♂ 5/1 5.6/1 0.661
Menopause ♀ (%) 87.2 89.5 0.536
BMI (kg/m
2) 25.3 ± 3.8 28.7 ± 5.0 0.000
Fracture (%) 21 24.6 0.000
Renal lithiasis (%) 6 36.0 0.000
25-OH-VitD (ng/mL ) 20.4 (6-42) 17.2 ± (3-93) 0.997
25-OH-VitD ≥ 30 ng/mL
(%)
15.2 9.2 0.221
Creatinine (mg/dL) 0.98 ± 0.14 1,02 ± 0.29 0.179
Total Calcium (mg/dL) 9.4 (8.6-10.6) 10.7 (9.8-14.5) 0.000
Ionized Calcium (mM) 1.23 (1.11-1.36) 1.47 (1.25-2.07) 0.000
PTH (pg/mL) 37 (10-105) 179 (59-1279) 0.000
Alk Phosphatase (U/L) 63.4 (33-198) 82.3 (20-373) 0.000
B Alk Phosphatase (U/L) 22.1 (11-53) 32.9 (5-85) 0.000
P1NP (μg/L) 46.3 (15-145) 54.9 (11-255) 0.005
Crosslaps B (ng/mL) 0.475 (0.053-
1.460)
0.814 (0.044-
3.208)
0.000
Osteocalcin (ng/mL) 19.4 (6-39) 30.9 (7-175) 0.000
Serum OPG (pmol/L) 3.0 (0.89-5.61) 4.8 (0.01-12.42) 0.000
LS_BMD (g/cm
2) 0.935 ± 0.134 0.879 ± 0.155 0.000
FemNeck_BMD (g/cm
2) 0.749 ± 0.120 0.691 ± 0.104 0.000
TotHip_BMD (g/cm
2) 0.887 ± 0.126 0.840 ± 0.145 0.000
Rad 1/3_BMD (g/cm
2) 0.671 ± 0.696 0.629 ± 0.102 0.000
Data shown as mean ± SD or median and range for non normal variables. B
Alk: bone alkaline. OPG: osteoprotegerin. LS: lumbar spine. Fem. Neck: femoral
neck. Tot Hip: total hip. 1/3 Rad: third distal radius. BMD: bone mineral
density. T Score: BMD related to peak bone mass. Z score: BMD related to
mean BMD in general population of equal age and gender.
+The 114 control
subjects were a subgroup from the 328 total control group age and gender
matched with the HPP patients.
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= 0.01) (Table 4). Analysis of BMD in the lumbar spine
or hip did not show any difference between genotypes.
Total calcium (mg/dL) GG = 12.3 ± 0.9; TT = 10.7 ±
0.7; TG = 10.9 ± 1.1 (p = 0.011); GG-TT p = 0.012 and
GG-TG p = 0.032, b Crosslaps (ng/mL) GG = 1.770 ±
2.033; TT = 0.816 ± 0.512; TG = 0.726 ± 0.356 (p =
0.033); GG-TT p = 0.035 and GG-TG p = 0.029 and
osteocalcin (ng/mL) GG = 175.0; TT = 30.4 ± 19.0; TG
= 30.6 ± 18.2 (p < 0.001); GG-TT p < 0.001 and GG-
TG p < 0.001 levels were significantly higher in the
minor homozygote allele group than in the other two
groups (Additional File 2). These results were not differ-
ent in the subgroup of women and we found no differ-
ence in their menopausal status between the three
genotype groups.
In the control group, we did not find any difference
between genotypes regarding BMD in the three sites
(Additional File 3).
SNP 1181 G/C OPG (rs 2073618)
In PHPT patients, BMD at all sites and bone remodelling
markers were similar in the three genotype groups (Addi-
tional File 2). These results were not different in the sub-
group of women and we found no difference in their
menopausal status between the three genotype groups.
In the control group, we found higher levels of BMD
(g/cm
2) in CC subjects vs in GG (0.983 ± 0.170 vs 0.872
± 0.155; p = 0.028) in the lumbar spine (Additional File
3).
SNP RANKL rs2277438
In PHPT patients, we found a non significant trend
towards lower BMD in the 1/3 distal radius (g/cm
2)
(AA = 0.622 ± 0.105; AG = 0.610 ± 0.087; GG = 0.543
± 0.074; p = 0.835), to lower BMD at total hip (g/cm
2)
(AA = 0.841 ± 0.132; AG = 0.821 ± 0.160; GG = 0.791
± 0.118; p = 0.502) and to higher levels of BAP (U/L)
(AA = 33.5 ± 17.3; AG = 29.9 ± 13.0; GG = 43.7 ± 8.4;
p = 0.122) in the minor allele homozygote group (GG)
versus the other two groups (Additional File 2). These
results were not different in the subgroup of women
and we found no difference in their menopausal status
between the three genotype groups.
In the control group, we did not find any differences
between genotypes regarding BMD at three sites (Addi-
tional File 3).
Due to the low frequency of one of the homozygous
genotypes in the OPG rs3102735 (163 A/G), OPG
rs3134070 (245 T/G) and RANKL rs2277438, we
grouped the heterozygote and the less frequent homozy-
gous subjects. We did not find any differences between
the groups regarding BMD in all sites.
Discussion
As expected, subjects in the PHPT group had high levels
of calcium, PTH, bone remodelling markers and low
BMD at the three studied sites. We found BMI corre-
sponding to overweight in the PHPT group consistent
with previous studies [32,33] although the nature of this
relationship remains uncertain. We found no differences
in vitamin D levels between patients and control sub-
jects, as Vignali had also found in postmenopausal
PHPT women [34], and, in contrast with previous data
[35] showing lower vitamin D levels in PHPT patients
than in control subjects, we did not find such a differ-
ence between the study groups although we did not
evaluate seasonal factors as the aforementioned study
did. OPG serum levels were three times higher in our
PHPT patients than in a previous study on men and
women aged 62 with PHPT [36] and our PHPT subjects
had lower levels than a group of postmenopausal
women [37]. Despite there being no established refer-
ence values, OPG serum levels appear to be higher in
postmenopausal women than in other conditions as
PHPT.
Table 2 Allelic frequencies in both control and PHPT subjects
OPG rs3102735 163 A/G OPG rs3134070 245 T/G OPGrs2073618 1181 G/C RANKL_rs2277438
AA AG GG TT TG GG GG GC CC AA AG GG
Control = 328 73.8% 24.3% 1.9% 91.6% 7.6% 0.4% 26.2% 47.1% 26.8% 67.5% 30.8% 1.7%
PHPT = 298 70.2% 27.6% 2.2% 90.1% 9.3% 0.6% 27.1% 44.5% 28.3% 74.1% 24.3% 1.6%
Chi
2 : not statistically significant in any of the SNPs.
Table 3 Odds ratio between control and PHPT subjects
OPG rs3102735 OPG rs3134070 OPG rs2073618 RANKL_rs2277438
AG T G GCA G
Control = 328 564 92 625 29 326 330 543 113
PHPT = 298 500 96 564 32 295 301 514 82
OR = 1.18 CI [0.86-1.6] OR = 1.22 CI [0.82-1.79] OR = 1.01 CI [0.73-1.26] OR = 1.06 [0.77-1.44]
OR: Odds Ratio. CI : confidence interval.
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between PHPT and control groups, this means that
none of the studied SNPs appears to be a genetic factor
which predisposes for PHPT.
The main purpose of this study was to analyze the
relationship between BMD, or fractures, and three SNPs
of the OPG and the rs2277438 SNP of the RANKL in
PHPT. We did not find any differences in frequency of
fractures between genotypes in control nor in PHPT
subjects in all the SNPs studied according to data of
previous studies of OPG rs3102735 (163 A/G) [27] and
of OPG rs2073618 (1181 G/C) [27,28] on postmenopau-
sal women. These two studies neither did find any dif-
ferences in BMD. A study of OPG rs2073618 (1181 G/
C) described a 26% higher risk of hip fractures and 52%
higher of femoral neck fractures in CC homozygote
than GG homozygote women independent of BMD [24].
There are no fracture data related to RANKL rs2277438
SNP in the literature. The genetic variation that causes
SNPs appear not to have main influence on a clinical
event as relevant as fractures in PHPT and in non
PHPT population.
Significantly lower BMD in the 1/3 distal radius with
similar PTH levels were found in the minor homozy-
gotes (GG) compared to heterozygotes and major allele
homozygotes in both OPG rs3102735 (163 A/G) and
OPG rs3134070 (245 T/G) SNPs in PHPT but not in
control subjects. This could mean that these minor
homozygote individuals suffer from more specific corti-
cal BMD loss not mediated by PTH or creatinine serum
levels in PHPT. An association between the G allele of
the OPG rs3102735 (163 A/G) SNP and low BMD in
the forearm, low heel broadband ultrasound attenuation
(BUA) and low heel speed of sound (SOS) were
described in Danish women with and without hip or
forearm fractures [16]. In Hungarian women the GG
genotype of the OPG rs3102735 (163 A/G) was asso-
ciated with low hip BMD [17]. Nevertheless, Hsu
reported that males with the GG genotype of the OPG
rs3102735 (163 A/G) had very low risk of having
Table 4 Comparison between genotypes of the SNP 163 A/G OPG rs3102735 and 245 T/G OPG rs3134070 in PHPT
patients
163 A/G OPG rs3102735 p 245 T/G OPG rs3134070 p
AA 61.7 ± 12.4 TT 61.2 ± 12.8
Age AG 61.0 ± 14.2 0.449 TG 64.3 ± 14.7 0.298
(years) GG 67.8 ± 15.2 GG 70.5 ± 7.7
AA 28.8 ± 5.1 TT 28.6 ± 4.9
BMI AG 28.4 ± 4.7 0.793 TG 29.5 ± 5.1 0.663
(kg/m
2) GG 28.6 ± 3.5 GG 28.6 ± 3.5
AA 1.02 ± 0.32 TT 1.01 ± 0.30
Creatinine AG 1.02 ± 0. 22 0.580 TG 1.05 ± 0.23 0.836
(mg/dL) GG 0.89 ± 0.16 GG 1.03 ± 0.05
AA 140 (32-873) TT 134 (32-873)
PTH AG 144 (50-1279) 0.927 TG 203 (55-1279) 0.314
(pg/mL) GG 164 (61-747) GG 252 (132-373)
AA 0.879 ± 0.142 TT 0.869 ± 0.142
LS BMD AG 0.863 ± 0.147 0.473 TG 0.919 ± 0.162 0.234
(g/cm
2) GG 0.826 ± 0.267 GG 0.672
AA 0.680 ± 0.104 TT 0.680 ± 0.102
Fem. Neck AG 0.685 ± 0.092 0.136 TG 0.710 ± 0.090 0.151
BMD (g/cm
2) GG 0.751 ± 0.139 GG 0.747 ± 0.053
AA 0.834 ± 0.144 TT 0.833 ± 0.140
Total Hip AG 0.831 ± 0.128 0.241 TG 0.848 ± 0.134 0.484
BMD (g/cm
2) GG 0.906 ± 0.135 GG 0.881 ± 0.008
AA 0.629 ± 0.096 <0.05 TT 0.616 ± 0.097 <0.05
1/3 Rad AG 0.635 ± 0.103 AA-GG: 0,038 TG 0.654 ± 0.100 GG-TT: 0,003
BMD (g/cm
2) GG 0.501 ± 0.147 AG-GG: 0,037 GG 0.326 GG-TG: 0,01
Data shown as mean ± SD or median and range for non normal variables. LS: lumbar spine. Fem. Neck: femoral neck. 1/3 Rad: third distal radius. BMD: bone
mineral density. Number of subjects: OPG 163: AA = 205, AG = 86, GG = 6. OPG 245
TT = 266, TG = 30, GG = 2 (except for LS BMD and 1/3 Rad BMD GG data = 1 subject).
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Page 6 of 9extremely low BMD in the hip [30]. Regarding the OPG
rs3134070 (245 T/G) SNP, an association between the
GG genotype and low BMD has already been reported
in the radius and femoral neck in postmenopausal
women [18]. Several other studies failed to show this
association between OPG rs3102735 (163 A/G) or OPG
245 T/G [19,22,27,28,38].
We did not find any difference between genotypes of
the OPG rs2073618 (1181 G/C) SNP regarding BMD in
the PHPT subjects, a finding in accordance with previous
studies on menopausal women [27,28]. However, we did
find higher BMD in the lumbar spine in the CC than in
the GG genotype group in the healthy control subjects,
also in accordance with previous findings in the general
or postmenopausal osteoporotic populations
[15,19,21-24]. These findings could mean that the bone
loss in PHPT, mainly cortical, and in the osteoporotic
condition, mainly cancellous, is modulated by different
genetic factors. Some possible factors could be the G
allele of the OPG rs2073618 (1181 G/C) SNP favouring
lumbar spine bone loss in osteoporosis, or the G allele of
the OPG rs3134070 (245 T/G) and rs3102735 (163 A/G)
f a v o u r i n gc o r t i c a lb o n el o s si nP H P T .B u ti ts h o u l db e
also considered that the wrist is a non-weight bearing
site and therefore is free of external factors or remodel-
ling due to body weight or physical activity.
Consistent with studies in the non-PHPT population
[19,29,30] we did not find any significant difference
between genotypes of the RANKL rs2277438 SNP in
PHPT or in the control group.
The main limitations of our study are the low fre-
quency of the GG genotype in both the OPG rs3102735
(163 A/G) and rs3134070 (245 T/G) SNPs and that
there was a trend (not statistically significant) to differ-
ence in age between the GG and the rest of the groups.
Otherwise, our results are supported by the fact that
they are not reproducible in control subjects and that
these two SNPs are located in the same haplotype block
(promoter).
Conclusion
Our study provides the first evaluation of the relation-
ship between SNPs of the OPG/RANK system and
sporadic PHPT. Subjects with PHPT and GG genotype
for the OPG rs3102735 (163 A/G) and OPG rs3134070
(245 T/G) SNPs appear to be at risk of having a lower
BMD in the distal radius, which is mainly cortical bone.
This association did not appear to be mediated by any
difference in PTH serum levels. Further studies on lar-
ger PHPT populations, with complementary functional
evaluation, are needed to support our results.
Additional material
Additional file 1: “Distribution Of Fractures And Lithiasis Frequency
Among the Genotypes of the Snps Studied In Phpt Patients”. This
file contains two tables showing the distribution of fractures and lithiasis
frequency among the genotype groups of the OPG 163 A/G rs3102735,
OPG 245 T/G rs3134070, OPG 1181 G/C rs2073618 and RANKL rs2277438
in PHPT patients.
Additional file 2: “Comparison Of Biochemical Parameters Among
The Genotype Groups of the Snps Studied In Phpt Subjects”. This
file contains several tables showing the comparison of biochemical
parameters among the genotype groups of the OPG 163 A/G rs3102735,
OPG 245 T/G rs3134070, OPG 1181 G/C rs2073618 and RANKL rs2277438
in PHPT patients.
Additional file 3: “Bone Mineral Density Distribution Among The
Genotypes of the Snps Studied In Control Subjects”. This file
contains a table showing the distribution of BMD levels among the three
genotype groups of the OPG 163 A/G rs3102735, OPG 245 T/G rs3134070,
OPG 1181 G/C rs2073618 and RANKL rs2277438 in the control subjects.
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Single nucleotide polymorphism; ELISA: Specific immunoassay; SD: Standard
deviation of the mean; SPSS: Statistical Package for Social Sciences; DXA: X-
ray absorptiometry.
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